Nucleic acid polymers (
NAPs) block the release of
HBsAg from infected hepatocytes. These compounds have been previously shown to have the unique ability to eliminate serum
surface antigen in DHBV-infected Pekin ducks and achieve multilog reduction of
HBsAg or
HBsAg loss in patients with chronic HBV
infection and HBV/HDV
coinfection. In ducks and humans, the blockage of
HBsAg release by
NAPs occurs by the selective targeting of the assembly and/or secretion of subviral particles (SVPs). The clinically active NAP species
REP 2055 and
REP 2139 were investigated in other relevant animal models of HBV
infection including woodchucks chronically infected with WHV, HBV transgenic mice and HBV infected SCID-Hu mice. The liver accumulation of
REP 2139 in woodchucks following subcutaneous administration was examined and was found to be similar to that observed in mice and ducks. However, in woodchucks, NAP treatment was associated with only mild (36-79% relative to baseline) reductions in WHsAg (4/10 animals) after 3-5 weeks of treatment without changes in serum WHV
DNA. In HBV infected SCID-Hu mice,
REP 2055 treatment was not associated with any reduction of
HBsAg,
HBeAg or HBV
DNA in the serum after 28 days of treatment. In HBV transgenic mice, no reductions in serum
HBsAg were observed with
REP 2139 with up to 12 weeks of treatment. In conclusion, the
antiviral effects of
NAPs in DHBV infected ducks and patients with chronic HBV
infection were weak or absent in woodchuck and mouse models despite similar liver accumulation of
NAPs in all these species, suggesting that the mechanisms of SVP assembly and or secretion present in rodent models differs from that in DHBV and chronic HBV
infections.